Phase II Randomized Controlled Trial of Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 May 2016
At a glance
- Drugs Peginterferon alfa-2b (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 19 May 2016 Status changed from recruiting to active, no longer recruiting.
- 19 May 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017.
- 14 Apr 2013 Status changed from not yet recruiting to recruiting as reported by Mayo Clinic.